AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Frelii Launches New Corporate and Investor Website

March 18, 2019

LEHI, Utah--(BUSINESS WIRE)--Mar 18, 2019--Frelii Inc. (OTCQB: FRLI) (“Frelii” or “The Company”) today announced that it has launched a new website, which can be visited at www.frelii.com. The objective with this new interactive website is to provide potential clients, partners and investors an engaging and thoughtful platform to learn about Frelii products, services and solutions while empowering visitors to access information based on their specific interests and industries.

The site provides information and insight into how Frelii’s advanced artificial intelligence (AI) platform and DNA analysis is impacting several industry segments including: Medical Cannabis, Precision Medicine, Mobile Health Technology, Hospital Systems, Corporate Wellness and Insurance.

“We are pleased to unveil the new Frelii corporate website to our investors, customers, clients, partners, media and visitors who are looking to better understand the depth and scope of our highly advanced AI and DNA analysis technology and solutions,” said Ian Jenkins, CEO of Frelii Inc. “The previous website was focused primarily on consumer applications. Our objective with the new website is to improve usability for the various industry segments we are expanding into with an engaging and informative visitor experience. The new design provides us with a foundation we can leverage for future growth and expansion.”

The new Frelii website will be regularly updated with news, information and insight regarding Frelii products, strategic initiatives, partnerships, events and industry developments.

About Frelii Inc.

Frelii Inc. is a medical technology company that uses gene sequencing and artificial intelligence to determine risk and lifestyle modifications. Its technology analyzes the most comprehensive markers (60,000,000+) on the market to date. Frelii’s technology generates accurate and profoundly valuable insight into DNA. It opens opportunities never before realized in health care, precision medicine, insurance, corporate wellness as well as personal health and risk identification. For more information, please visit  www.frelii.com. Frelii (OTCQB: FRLI) trades on the #OTCQB Venture Market for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on  www.otcmarkets.com.

Follow Frelii online at:

Frelii Facebook Page  https://www.facebook.com/livefrelii/
Frelii Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
Frelii LinkedIn Page linkedin.com/company/frelii/

Safe Harbor Statement:

This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190318005565/en/

CONTACT: Media Contact:

Tim Rush

Springboard5

801-208-1100

tim.rush@springboard5.com

KEYWORD: UNITED STATES NORTH AMERICA UTAH

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS

SOURCE: Frelii Inc.

Copyright Business Wire 2019.

PUB: 03/18/2019 12:04 PM/DISC: 03/18/2019 12:04 PM

http://www.businesswire.com/news/home/20190318005565/en